|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis显示文摘AIM:To search for the answer in extensive ulcerative colitis as to whether histological inflammation persisting despite endoscopic mucosal healing serves to increase the risk of colon cancer(CC)or high grade dysplasia(HGD).METHODS:This is a single center(Lenox Hill Hospital)retrospective cohort and descriptive study of extensive ulcerative colitis(UC)for 20 years or more with a minimum of 3 surveillance colonoscopies and biopsies performed after the first 10 years of UC diagnosis.Data analyzed included:duration of UC,date of diagnosis of(CC)or(HGD),number of surveillance colonoscopies,and biopsies showing histological inflammation and its severity in each of 6 segments when endoscopic appearance is normal.Two subgroups of patients were compared:group 1 patients who developed CC/HGD and group 2 patients who did not develop CC/HGD.RESULTS:Of 115 patients with longstanding UC reviewed,68 patients met the inclusion criteria.Twenty patients were in group 1 and 48 in group 2.We identified the number of times for each patient when the endoscopic appearance was normal but biopsies nevertheless showed inflammation.Overall,histological disease activity in the absence of gross/endoscopic disease was found in 31.2%(95%CI:28%-35%)of colonoscopies performed on the entire cohort of 68 patients.Histological disease activity when the colonoscopy showed an absence of gross disease activity was more common in group 1 than group 2 patients,88%(95%CI:72%-97%)vs 59%(95%CI:53%-64%).Only 3/20(15%)of patients in group 1 ever had a colonoscopy completely without demonstrated disease activity(i.e.,no endoscopic or histological activity)as compared to 37/48(77%)of patients in group 2,and only 3.3%(95%CI:0.09%-8.3%)of colonoscopies in group 1 had no histological inflammation compared to23%(95%CI:20%-27%)in group 2.CONCLUSION:Progression to HGD or CC in extensive ulcerative colitis of long standing was more frequently encountered among those patients who demonstrate persistent histological inflammation in the absence of gross mucosal disease.Our findings support including the elimination of histological inflammation in the definition of mucosal healing,and support this endpoint as an appropriate goal of therapy because of its risk of increasing dysplasia and colon cancer. | Burton I Korelitz Keith Sultan Megha Kothari Leo Arapos Judy Schneider Georgia Panagopoulos | 2014 | World Journal of Gastroenterology2014，20，17： | 4 |
| 2 | Choice of laxatives and colonoscopic preparation in pregnant patients from the viewpoint of obstetricians and gastroenterologists显示文摘AIM: To elucidate the preferences of gastroenterologists at our institution and compare them to those of obstetricians when making decisions in the pregnant patient, including which type of bowel preparations to use for ? exible sigmoidoscopy or colonoscopy, as well as which laxatives can be used safely. METHODS: Surveys were mailed to all attending gastroenterologists (n = 53) and obstetricians (n = 99) at our institution. Each survey consisted of the 14 most common laxative or motility agents used in pregnancy and inquired about the physician’s prescribing habits in the past as well as their willingness to prescribe each medication in the future. The survey also listed four common bowel preparations used prior to colonoscopy and sigmoidoscopy and asked the physician to rank the order of the preferred agent in each case. RESULTS: With regard to common laxatives, both gastroenterologists and obstetricians favor the use of Metamucil, Colace, and Citrucel. Both groups appear to refrain from using Fleets Phosphosoda and Castor oil. Of note, obstetricians are less inclined to use PEG solution and Miralax, which is not the case with gastroenterologists. In terms of comparing bowel preparations for colonoscopy, 50% of gastroenterologists prefer to use PEG solution and 50% avoid the use of Fleets Phosphosoda. Obstetricians seem to prefer Fleets Phosphosoda (20%) and tend to avoid the use of PEG solution (26%). With regard to bowel preparation for sigmoidoscopy, both groups prefer Fleets enema the most (51%), while magnesium citrate is used least often (38%). CONCLUSION: It is clear that preferences in the use ofbowel cleansing preparations between the two groups exist, but there have not been many case controlled human studies in the pregnant patient that give clear cut indications for using one versus another drug. In light of the challenge of performing controlled trials in pregnant women, more extensive surveys should be undertaken to gather a larger amount of data on physicians’ experiences and individual preferences. | Jeevan Vinod Jennifer Bonheur Burton I Korelitz Georgia Panagopoulos | 2007 | World Journal of Gastroenterology2007，13，48： | 4 |
| 3 | Induction and prevention of acceleration atelectasis显示文摘 | TACKER W A J R BALLDIN U I BURTON R R | 1987 | Aviat Space Environ Med1987，58，1： | 1 |
| 4 | Community level adaptation to climate change : the potential role of participatory community risk assessment 显示文摘 | van Aalst M K Cannon T Burton I | 2008 | Global Environmental Change2008，18，1： | 1 |
| 5 | Similarity analysis of industrial alarm flood data 显示文摘 | Ahmed K Izadi I Chen Tongwen Joe D Burton T | 2013 | Automation Science and Engineering IEEE Transactions on2013，10，2： | 1 |
| 6 | Adverse events after imatinib mesylate therapy 显示文摘 | Burton C Azzi A Kerridge I | 2002 | N Engl J Med2002，346，9： | 1 |
| 7 | Point prevalence survey of antibiotic use in Scottish hospitals utilising the Glasgow Anti- microbial AuditTool (GAAT)显示文摘 | Seaton RA Nathwani I) Burton P | 2007 | Int J Antimicrob Agents2007，29，6： | 1 |
| 8 | Evidence for involvement of cyclic GMP phosphodiesterase in morphine tolerance 显示文摘 | Burton C K Ho I K Hoskins B | 1990 | J Pharmacol Exp Ther1990，252，1： | 1 |
| 9 | On the estimation of average crystallite size of zeolite from the Scherrer equation : A critical evaluation of its application to zeolites with one - dimensional pore systems 显示文摘 | Burton A W Ong K Thomas R Chan I Y | 2009 | Micropor Mesopor Mater2009，117，： | 1 |
| 10 | Phase I study of the heat shock protein 90 inhibitor alvespimycin ( KOS-1022, 17-DMAG) administered intravenously twice weekly to pa- tients with acute myeloid leukemia显示文摘 | Lancet JE Gojo I Burton M | 2010 | Leukemia2010，24，： | 1 |
| 11 | Quantitative 1H NMR with external standards: use in preparation of calibration solu- tions for algal toxins and other natural products 显示文摘 | Burton I W Quilliam M A Walter J A | 2005 | Anal Chem2005，77，10： | 1 |
| 12 | MRIidentified prognostic features of tumors in distal sigmoid,rectosigmoid, and upper rectum : treatment withradiotherapy and chemotherapy 显示文摘 | BURTON S BROWN G DANIELS I | 2006 | Int J Radi at OncolBiol Phys2006，65，2： | 1 |
| 13 | Interrater Reliability of the Functional Movement 显示文摘 | MINICK I K KIESEL B K BURTON L | 2010 | Journal of Strength and Conditioning Research2010，24，2： | 1 |
| 14 | From impact assessment of adap-tation priorities:the shaping of adaptation policy显示文摘 | Burton I Huq S Lim B | 2002 | Climate Policy2002，2，： | 1 |
| 15 | Sorption and desorption behavior of tributyltin with natural sediments 显示文摘 | Burton E D Phillips I R Hawker D W | 2004 | Environ Sci Technol2004，38，24： | 1 |
| 16 | Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study显示文摘 | Joseph B Felder Burton I Korelitz Ramona Rajapakse Samuel Schwarz Angelo P Horatagis Gilbert Gleim | 2000 | The American Journal of Gastroenterology2000，，： | 1 |
| 17 | Expert opinion: Experience with 6-mercaptopurine in the treatment of inflammatory bowel disease显示文摘Arbitrarily, modern day treatment of inflammatory bowel disease begins with the introduction of immuno- suppressives for ulcerative colitis. Clinical improvement with sulfasalazine had been meaningful but modest. Treatment with adrenocorticotropic hormone and corti- costeroids led to clinical responses never before realized but it took much too long to recognize that they were not capable of maintaining remission, that adverse reactions were subtle but potentially devastating and that some other agent would be necessary to capitalize on their transient advantage. This of course was true in the treatment of Crohn's disease as well. Not much was ever made of the role of sulfasalazine for Crohn' s disease, but with the severing of the diazobond and the elimination of the sulphur component, the 5-ami- nosalacylic acid (5-ASA) products clearly led to clinical improvement, especially in cases of Crohn's colitis and those with ileitis where the 5-ASA product was released in the terminal ileum and more proximal in the small bowel as well as in ulcerative colitis. The induction of remission was first demonstrated by 6-mercaptopurine (6-MP) with case reports and uncontrolled trials in pa- tients with ulcerative colitis, but its placebo controlled trial for Crohn's disease firmly established its role in inducing remission. No subsequent trial has confirmed its similar role for ulcerative colitis, but nevertheless cli- nicians know well that 6-MP works at least as well and probably more effectively for ulcerative colitis than for Crohn's disease. What changes have taken place utiliz- ing 6-MP in the management of inflammatory bowel disease since its introduction in the 1960's and 1970's and its trial for Crohn's disease published in the New England Journal of Medicine in 1980? | Burton I Korelitz | 2013 | World Journal of Gastroenterology2013，19，20： | 1 |
| 18 | Adverse events after imatinib mesylate therapy显示文摘 | Burton C Azzi A Kerridge I | 2002 | N Engl J Med2002，346，9： | 1 |
| 19 | Structural characterization of the antimicrobial peptide pleurocidin from winter flounder显示文摘 | Syvitski RT Burton I Mattatall N R | | 0，，19： | 1 |
| 20 | Structure and synthesis of SSZ-63: Toward an ordered form of zeolite Beta显示文摘 | Burton A W Elomari S Chan I | 2005 | J Phys Chem B2005，109，20： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员